JERUSALEM, Oct. 01, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today they will be hosting “Advances in Neuromodulation for the Treatment of Neuropsychiatric Conditions”, an innovation showcase on their deep transcranial magnetic stimulation (Deep TMS™) device, as well as other educational activities, during the Psych Congress Meeting being held from October 3-6 in San Diego, CA.
Manish Sheth, MD, Ph.D., from Achieve TMS will be presenting at the innovation showcase and will discuss key advances in neuromodulation, such as Deep TMS, to treat a number of neuropsychiatric conditions, including Major Depressive Disorder (MDD) as well as Obsessive Compulsive Disorder (OCD).
SHOWCASE PRESENTATION DETAILS
BrainsWay is also exhibiting at the conference and offering hands-on demonstrations of the Deep TMS device, allowing physicians to experience first-hand how the device can easily and seamlessly be integrated into their practice. Educational materials featuring statistically significant data from the recent landmark European study, demonstrating that Deep TMS plus standard medication is significantly more effective at reducing depression levels among MDD patients compared with standard medication-alone, will also be available at the booth.
“This year’s Psych Congress provides BrainsWay an excellent setting to showcase our innovative Deep TMS technology and recent results from the landmark European study, which continues to propel us forward,” said David Zacut, MD, founder and chairman of the board of BrainsWay. “We will continue to support physicians as they further integrate Deep TMS into the standard of care protocol for their patients who are living with treatment-resistant MDD and OCD.”
For more information, visit us at booth #121 or www.brainsway.com
About Psych Congress
Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—psychiatrists, physician assistants, nurse practitioners, psychologists, primary care physicians, and other mental health professionals—with the foremost experts in mental health to improve patient outcomes through education.
About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
